Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Dasatinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 13 Sep 2018 Planned End Date changed from 1 Aug 2018 to 31 Aug 2018.
- 13 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 31 Aug 2018.
- 24 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History